
Opinion|Videos|June 23, 2025
Overcoming Challenges for Wider Adoption of TLX250
Panelists discuss how molecular imaging might help with complex renal mass decision-making, potentially identifying aggressive clear cell biology that would warrant radical rather than partial nephrectomy, though anatomical details would still require conventional imaging.
Advertisement
Episodes in this series

Complex Renal Masses and Molecular Imaging
Main Discussion Topics:
- Challenges of managing anatomically complex renal masses
- Potential for molecular imaging to influence nephron-sparing decisions
- Tumors with aggressive biology may warrant radical nephrectomy, whereas those with indolent biology may be candidates for partial nephrectomy.
- Limitations in anatomic resolution compared with MRI
Key Points for Physicians:
- Molecular characteristics may influence decisions regarding partial vs radical nephrectomy.
- Aggressive biology might favor radical approach, even when partial is technically feasible.
- Indolent biology might support nephron sparing, even in challenging cases.
- Molecular imaging should complement rather than replace high-resolution anatomic imaging.
Notable Insights:
Molecular imaging provides biological rather than anatomic information and should be used in conjunction with conventional imaging for optimal decision-making.
Clinical Significance:
Integrating molecular and anatomic imaging could lead to more personalized surgical approaches based on both technical feasibility and biological risk.
Advertisement
Related to this article

Jessica Rett, PhD, joins Adam B. Weiner, MD, to discuss how medical terminology and common metaphors shape patient understanding and communication in cancer care.

Aaron Berger, MD, discusses testosterone recovery after prostate cancer therapy interruption and its implications for quality of life, PSA kinetics, and treatment decisions.

Kiran Sury, MD, discusses patient selection, durability, and adverse events with ProACT for male stress urinary incontinence.

The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.

American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
2
FDA approves durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC
3
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
4
The UroOnc Minute: The Role of Language in Cancer Care, With Jessica Rett, PhD
5


